Beijing has gone on to release a new policy so as to promote the development when it comes to the medical device industry in China, stressing strong support in terms of digitalization and application of artificial intelligence within the sector.
The policy, which has been jointly issued by the Beijing Municipal Bureau of Economy and Information Technology as well as five other departments on November 24, 2025, goes on to support the medical device industry in China and also makers in allying along with the large language model firms in order to develop and also roll out certain industry-specific LLMs. For projects that attain domestic first-class as well as global leading benchmarks, almost CNY30 million, which is equivalent to USD4.2 million, is going to be provided based upon the computing power costs.
The policy also encourages the medical institutions to go ahead and integrate new AI diagnostic and treatment technologies within their present practices and also establish pricing benchmarks that are based on the present prices. For innovative projects, it goes on to support the institutions to initiate trials as per a conditionally added approach, with selected promotion as well as application of AI-assisted diagnostic and also treatment projects, which would be able to get around 30% of the investment, but with a cap of CNY50 million.
Besides this, the policy also promotes open cooperation as well as international expansion for innovative medical devices. For those devices that already have received an approval from global regulators such as the US Food and Drug Administration, the Pharmaceuticals and Medical Devices Agency of Japan, the European Conformity, the Therapeutic Goods Administration of Australia, regulatory agencies across the BRICS countries, and also the World Health Organization, and have been approved within the related foreign markets, there would be a certain level of support that will be offered for their registration application costs, with a maximum amount for a single product of CNY1 million or USD140,935 and for a single firm of CNY3 million every year.
Additionally, the policy also goes on to cover the research and development registration pertaining to innovative medical devices, clustering of supply chains, transformation and application of results, and overseas expansion, as well as certain other aspects. For example, almost CNY2 million can be awarded when it comes to innovative medical devices hitting the market, CNY10 million for companies having quite an outstanding clinical promotion outcome, and also CNY50 million when it comes to building industrial facilities.
The policy is going to be effective from the date of its release till December 31, 2028.
